Thymosin Alpha-1 — 10mg | TA1 Thymic Peptide

Thymosin Alpha-1 (TA1, Tα1) is a synthetic version of a naturally occurring 28-amino-acid N-acetylated peptide originally isolated from thymosin fraction 5 of bovine thymus by Allan Goldstein and colleagues in 1977. The compound is one of the most extensively studied thymic peptides in immunology research, with academic literature spanning more than four decades. Mechanistically, TA1 has been investigated for binding to TLR2 (Toll-like receptor 2) and TLR9, with downstream effects on MyD88 signaling cascades, NF-κB pathway activation, and dendritic cell maturation markers. The compound has been investigated extensively in preclinical and clinical research literature for innate immune cell pharmacology, T-cell maturation marker research, and comparative immune-modulating peptide SAR studies (Goldstein, Romani, Garaci, and colleagues). TA1 is used here primarily as a research tool for TLR-mediated innate immunity pharmacology and structure-activity relationship studies of thymic peptides. The compound has undergone clinical trial investigation for several research indications outside North America, though it remains an investigational research compound in US and Canadian markets without approved regulatory status.

Benefits (Research Focus)

• TLR2 / TLR9 receptor pharmacology — studied for binding activity at Toll-like receptors and downstream signaling research

• Dendritic cell research — investigated for dendritic cell maturation marker expression in cell research models

• MyD88 / NF-κB pathway research — explored for innate immune signaling cascade endpoints in cell culture systems

• T-cell maturation research — examined for T-lymphocyte differentiation marker expression in thymocyte cell research

• Comparative thymic peptide research — researched alongside other thymic-derived peptides (Thymogen, Vilon, Thymalin) for SAR studies

What Researchers Look At

• TLR2 and TLR9 receptor binding affinity and selectivity profiles

• Dendritic cell maturation markers (CD80, CD86, MHC-II) in dendritic cell research

• MyD88-dependent signaling cascade activation and NF-κB nuclear translocation

• T-lymphocyte differentiation markers (CD3, CD4, CD8) in thymocyte cell research

• Comparative pharmacology versus other thymic peptide research compounds and TLR agonists

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 10 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Thymosin Alpha-1 (TA1, Tα1)

• Synonyms: Thymalfasin; Tα1; thymic peptide alpha-1

• Class: Synthetic N-acetylated 28-amino-acid peptide; thymic peptide research compound; TLR2/TLR9 research agonist

• Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH (28 amino acids with N-terminal acetylation)

• Origin: First isolated from thymosin fraction 5 by Allan Goldstein and colleagues (George Washington University, 1977)

• Formula / M.W.: C₁₂₉H₂₁₅N₃₃O₅₅, ~3108.27 g/mol

• CAS: 62304-98-7

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Thymosin Alpha-1 Janoshik Verification — September 10, 2025

• Thymosin Alpha-1 VPeptide — April 23, 2026

• Thymosin Alpha-1 VPeptide — Sep  25 2026